Hypothesis Prolactin is tumorigenic to human breast: Dispelling the myth that prolactin-induced mammary tumors are rodent-specific

Journal of Applied Toxicology

Volumn 32, Issue 1, 2012, Pages 1-9

  Harvey, Philip W ^a  

^a UK   (United Kingdom)

Author keywords

Breast; Cancer; Carcinogenesis; Carcinogenicity bioassay; Human; Hyperprolactinemia; Mammary; Mechanism; Prolactin; Prolactin receptor; Rat; Risk extrapolation; Rodent; Tumor promotion; Tumorigenesis

Indexed keywords

PROLACTIN;

BIOASSAY; BREAST CANCER; CANCER CELL; CANCER RISK; CARCINOGENESIS; CARCINOGENICITY; DISEASE ASSOCIATION; HORMONE BLOOD LEVEL; HUMAN; MOLECULAR BIOLOGY; PRIORITY JOURNAL; REVIEW;

ANIMALS; BREAST NEOPLASMS; CELL LINE, TUMOR; CELL PROLIFERATION; ESTROGENS; FEMALE; HUMANS; MAMMARY NEOPLASMS, EXPERIMENTAL; MICE; PITUITARY GLAND; PROLACTIN; RECEPTORS, PROLACTIN;

RATTUS; RODENTIA;

EID: 83555175945     PISSN: 0260437X     EISSN: 10991263     Source Type: Journal    
DOI: 10.1002/jat.1772     Document Type: Review

References (88)

1. Aksamitiene E, Achanta S, Kolch W, Kholodenko BN, Hoek JB, Kiyatkin A. 2011. Prolactin-stimulated activation of ERK1/2 mitogen-activated protein kinases is controlled by PI3-kinase/Rac/PAK signaling pathway in breast cancer cells. Cell. Signal. 23: 1794-1805.
2. Arendt LM, Schuler LA. 2008. Prolactin drives estrogen receptor-alpha-dependent ductal expansion and synergizes with transforming growth factor-alpha to induce mammary tumors in males. Am. J. Pathol. 172: 194-202.
3. Arendt LM, Evans LC, Rugowski DE, Garcia-Barchino MJ, Rui H, Schuler LA. 2009. Ovarian hormones are not required for PRL-induced mammary tumorigenesis, but estrogen enhances neoplastic processes. J. Endocrinol. 203: 99-110.
4. Baldrick P. 2005. Carcinogenicity evaluation: comparison of tumor data from dual control groups in Sprague-Dawley rat. Toxicol. Pathol. 33: 283-291.
5. Ben-Jonathan N, Liby K, McFarland M, Zinger M. 2002. Prolactin as an autocrine/paracrine growth factor in human cancer. Trends Endocrinol. Metab. 13: 245-250.
6. Bernichtein S, Touraine P, Goffin V. 2010. New concepts in prolactin biology. J. Endocrinol. 206: 1-11.
7. Bhatavdekar JM, Patel DD, Shah NG, Vora HH, Suthar TP, Ghosh N, Chikhlikar PR, Trivedi TI. 2000. Prolactin as a local growth promoter in patients with breast cancer: GCRI experience. Eur. J. Surg. Oncol. 26: 540-547.
8. Bostwick JR, Guthrie SK, Ellingrod VL. 2009. Antipsychotic-induced hyperprolactinemia. Pharmacotherapy 29: 64-73.
9. Carver KC, Arendt LM, Schuler LA. 2009. Complex prolactin crosstalk in breast cancer: new therapeutic implications. Mol. Cell. Endocrinol. 307: 1-7.
10. Clevenger CV. 2003. Role of prolactin/prolactin receptor signaling in human breast cancer. Breast Dis. 18: 75-86.
11. Clevenger CV, Furth PA, Hankinson SE, Schuler LA. 2003. The role of prolactin in mammary carcinoma. Endocr. Rev. 24: 1-27.
12. Clevenger CV, Zheng J, Jablonski EM, Galbaugh TL, Fang F. 2008. From bench to bedside: future potential for the translation of prolactin inhibitors as breast cancer therapeutics. J. Mammary Gland Biol. Neoplasia 13: 147-156.
13. Clevenger CV, Gadd SL, Zheng J. 2009. New mechanisms for PRLr action in breast cancer. Trends Endocrinol. Metab. 20: 223-229.
14. Cohen SM, Klaunig J, Meek E, Hill RN, Pastoor T, Lehman-McKeeman L, Bucher J, Longfellow DG, Seed J, Dellarco V, Fenner-Crisp P, Patton D. 2004. Evaluating the human relevance of chemically induced animal tumors. Toxicol. Sci. 78: 181-186.
15. Cueto Ladron de Guevara J, Villalba Moreno J, Garcia Puche JL, Pedraza V. 1985 Prolactin and human cancer of the breast. 1. Levels of correlation. Rev. Esp. Oncol. 32: 439-458.
16. Das R, Vonderhaar BK. 1997. Prolactin as a mitogen in mammary cells. J. Mammary Gland Biol. Neoplasia 2: 29-39.
17. Dong J, Tsai-Morris CH, Dufau ML. 2006. A novel estradiol/estrogen receptor α-dependent transcriptional mechanism controls expression of the human prolactin receptor. J. Biol. Chem. 281: 18825-18836.
18. Drosdowsky M, Edery M, Guggiari M, Montes-Rendon A, Rudali G, Vives C. 1980 Inhibition of prolactin-induced mammary cancer in C3Hf (XVII) mice with the trans isomer of bromotriphenylethylene. Cancer Res. 40: 1674-1679.
19. Eliassen AH, Tworoger SS, Hankinson SE. 2007. Reproductive factors and family history of breast cancer in relation to plasma prolactin levels in premenopausal and postmenopausal women. Int. J. Cancer 120: 1536-1541.
20. Faupel-Badger JM, Sherman ME, Garcia-Closas M, Gaudet MM, Falk RT, Andaya A, Pfeiffer RM, Yang XR, Lissowska J, Brinton LA, Peplonska B, Vonderhaar BK, Figueroa JD. 2010. Prolactin serum levels and breast cancer: relationships with risk factors and tumour characteristics among pre- and postmenopausal women in a population-based case-control study from Poland. Br. J. Cancer 103: 1097-1102.
21. Fernandez I, Touraine P, Goffin V. 2010. Prolactin and human tumorogenesis. J. Neuroendocrinol. 22: 771-777.
22. Fritze D, Queisser W, Schmid H, Kaufmann M, Massner B, Westerhausen M, Schmidt R, Edler L, Abel U. 1986. Prospective randomized trial concerning hyper- and normoprolactinemia and the use of bromoergocriptine in patients with metastatic breast cancer. Onkologie 9: 305-312.
23. Frontini L, Lissoni P, Vaghi M, Perego MS, Pescia S, Ardizzoia A, Gardani G. 2004. Enhancement of the efficacy of weekly low-dose taxotere by the long acting anti-prolactinemic drug cabergoline in pretreated metastatic breast cancer. Anticancer Res. 24: 4223-4226.
24. Galsgaard ED, Rasmussen BB, Folkesson CG, Rasmussen LM, Berchtold MW, Christensen L, Panina S. 2009. Re-evaluation of the prolactin receptor in human breast cancer. J. Endocrinol. 201: 115-128.
25. Goffin V, Touraine P, Pichard C, Bernichtein S, Kelly P. 1999. Should prolactin be reconsidered as a therapeutic target in human breast cancer? Mol. Cell. Endocrinol. 151: 79-87.
26. Goffin V, Bernichtein S, Touraine P, Kelly PA. 2005. Development and potential clinical uses of human prolactin receptor antagonists. Endocr. Rev. 26: 400-422.
27. Goffin V, Touraine P, Culler MD, Kelly PA. 2006. Drug Insight: prolactin-receptor antagonists, a novel approach to treatment of unresolved systemic and local hyperprolactinemia? Nat. Clin. Pract. Endocrinol. Metab. 2: 571-581.
28. Gold LS, Slone TH, Manley NB, Bernstein L. 1991. Target organs in chronic bioassays of 533 chemical carcinogens. Environ. Health Perspect. 93: 233-246.
29. González L, Zambrano A, Lazaro-Trueba I, Lopéz E, González JJ, Martín-Pérez J, Aranda A. 2009. Activation of the unliganded estrogen receptor by prolactin in breast cancer cells. Oncogene 28: 1298-1308.
30. Goodman G, Bercovich D. 2008. Prolactin does not cause breast cancer and may prevent it or be therapeutic in some conditions. Med. Hypotheses 70: 244-251.
31. Gopinath C. 1995. The predictive value of pathological findings in animal toxicity studies. J. Toxicol. Pathol. 8: 89-100.
32. Gopinath C. 1999. Comparative endocrine carcinogenesis. In Endocrine and Hormonal Toxicology, Harvey PW, Rush KC, Cockburn A (eds). Wiley: Chichester.
33. Greendale GA, Huang MH, Ursin G, Ingles S, Stanczyk F, Crandall C, Laughlin GA, Barrett-Connor E, Karlamangla A. 2007. Serum prolactin levels are positively associated with mammographic density in postmenopausal women. Breast Cancer Res. Treat. 105: 337-346.
34. Hankinson SE. 2005. Endogenous hormones and risk of breast cancer in postmenopausal women. Breast Dis. 24: 3-15.
35. Hankinson SE. 2008. Circulating levels of sex steroids and prolactin in premenopausal women and risk of breast cancer. Adv. Exp. Med. Biol. 617: 161-169.
36. Hankinson SE, Willett WC, Michaud DS, Manson JE, Colditz GA, Longcope C, Rosner B, Speizer FE. 1999. Plasma prolactin levels and subsequent risk of breast cancer in postmenopausal women. J. Natl. Cancer Inst. 91: 629-634.
37. Hargreaves A, Harleman J. 2011. Preclinical risk assessment of drug-induced hypo- and hyperprolactinemia. J. Appl. Toxicol. 31: 599-607.
38. Harvey PW. 2005. Human relevance of rodent prolactin-induced non-genotoxic mammary carcinogenesis: prolactin involvement in human breast cancer and significance for toxicology risk assessments. J. Appl. Toxicol. 25: 179-183.
39. Harvey PW, Sutcliffe C. 2010. Adrenocortical hypertrophy: establishing cause and toxicological significance. J. Appl. Toxicol. 30: 617-626.
40. Harvey PW, Everett DJ, Springall CJ. 2006. Hyperprolactinaemia as an adverse effect in regulatory and clinical toxicology: role in breast and prostate cancer. Hum. Exp. Toxicol. 25: 395-404.
41. Harvey PW, Everett DJ, Springall CJ. 2008. Adverse effects of prolactin in rodents and humans: breast and prostate cancer. J. Psychopharmacol. 22: 20-27.
42. Holtkamp W, Nagel GA. 1988. Bromocriptine in chemotherapy resistant, metastatic breast cancer. Results of the GO-MC-BROMO 2/82 AIO study. Onkologie 11: 121-127.
43. Holtkamp W, Nagel GA, Wander HE, Rauschecker HF, von Heyden D. 1984. Hyperprolactinaemia is an indicator of progressive disease and poor prognosis in advanced breast cancer. Int. J. Cancer 34: 323-328.
44. Howell SJ, Anderson E, Hunter T, Farnie G, Clarke RB. 2008. Prolactin receptor antagonism reduces the clonogenic capacity of breast cancer cells and potentiates doxorubicin and paclitaxel cytotoxicity. Breast Cancer Res. 10: R68.
45. Idelman G, Jacobson EM, Tuttle TR, Ben-Jonathan N. 2011. Lactogens and estrogens in breast cancer chemoresistance. Expert Rev. Endocrinol. Metab. 6: 411-422.
46. Ingram DM, Nottage EM, Roberts AN. 1990. Prolactin and breast cancer risk. Med. J. Aust. 153: 469-473.
47. Jacobson EM, Hugo ER, Tuttle TR, Papoian R, Ben-Jonathan N. 2010. Unexploited therapies in breast cancer and prostate cancer: blockade of the prolactin receptor. Trends Endocrinol. Metab. 21: 691-698.
48. Jacobson EM, Hugo ER, Borcherding DC, Ben-Jonathan N. 2011. Prolactin in breast and prostate cancer: molecular and genetic perspectives. Discov. Med. 59: 315-324.
49. Key TJ. 2011. Endogenous oestrogens and breast cancer risk in premenopausal and postmenopausal women. Steroids 76: 812-815.
50. Kleinberg DL. 1987. Prolactin and breast cancer. New Engl. J. Med. 316: 269-271.
51. Kwa HG, Cleton F, Wang DY, Bulbrook RD, Bulstrode JC, Hatward JL, Millis RR, Cuzick J. 1981. A prospective study of plasma prolactin levels and subsequent risk of breast cancer. Int. J. Cancer 28: 673-676.
52. Lauber SN, Gooderham NJ. 2007. The cooked meat derived genotoxic carcinogen 2-amino-3-methylimidazo[4, 5-b]pyridine has potent hormone-like activity: mechanistic support for a role in breast cancer. Cancer Res. 67: 9597-9602.
53. LaPensee EW, Schwemberger SJ, LaPensee CR, Bahassi el M, Afton SE, Ben-Jonathan N. 2009. Prolactin confers resistance against cisplatin in breast cancer cells by activating glutathione-S-transferase. Carcinogenesis 30: 1298-1304.
54. LaPensee EW, Ben-Jonathan N. 2010. Novel roles of prolactin and estrogens in breast cancer: resistance to chemotherapy. Endocr. Relat. Cancer 17: R91-107.
55. Leondires MP, Hu ZZ, Dong J, Tsai-Morris CH, Dufau ML. 2002. Estradiol stimulates expression of two human prolactin receptor isoforms with alternative exons-1 in T47D breast cancer cells. J. Steroid Biochem. Mol. Biol. 82: 263-268.
56. Liby K, Neltner B, Mohamet L, Menchen L, Ben-Jonathan N. 2003. Prolactin overexpression by MDA-MB-435 human breast cancer cells accelerates tumor growth. Breast Cancer Res. Treat. 79: 241-252.
57. Lissoni P, Vaghi M, Villa S, Bodraska A, Cerizza L, Tancini G, Gardani GS. 2003. Antiprolactinemic approach in the treatment of metastatic breast cancer: a phase II study of polyneuroendocrine therapy with LHRH-analogue, tamoxifen and the long-acting antiprolactinemic drug carbergoline. Anticancer Res. 23(1B): 733-736.
58. Mershon J, Sall W, Mitchner N, Ben-Jonathan N. 1995. Prolactin is a local growth factor in rat mammary tumors. Endocrinology 136: 3619-3623.
59. Mujagić Z, Mujagić H. 2004. Importance of serum prolactin determination in metastatic breast cancer patients. Croat. Med. J. 45: 176-180.
60. Mujagić Z, Mujagić H, Prniavorac B. 2005. Circulating levels of prolactin in breast cancer patients. Med. Arh. 59: 33-35.
61. Murai I, Ben-Jonathan N. 1990. Acute stimulation of prolactinrelease by estradiol: mediation by posterior pituitary. Endocrinology 126: 3179-3184.
62. Nagasawa H, Morii S. 1982. Inhibition by early treatment with bromocriptine of spontaneous mammary tumour development in rats with no side effects. Acta Endocrinol. 101: 51-55.
63. Neumann F. 1991. Early indicators for carcinogenesis in sex-hormone sensitive organs. Mutat. Res. 248: 341-356.
64. Perks CM, Keith AJ, Goodhew KL, Savage PB, Winters ZE, Holly JM. 2004. Prolactin acts as a potent survival factor for human breast cancer cell lines. Br. J. Cancer 91: 305-311.
65. Peveler RC, Branford D, Citrome L, Dinan T, Fitzgerald P, Harvey PW, Holt RIG, Howard L, Kohen D, Jones I, O'Keane V, Pariente C, Pendlebury J, Smith S, Yeomans D. 2008. Antipsychotics and hyperprolactinaemia: clinical recommendations. J. Psychopharmacol. 22(suppl.): 20-27.
66. Plotnikov A, Varghese B, Tran TH, Liu C, Rui H, Fuchs SY. 2010. Impaired turnover of prolactin receptor contributes to transformation of human breast cancer cells. Cancer Res. 69: 3165-3172.
67. Rasmussen LM, Frederiksen KS, Din N, Galsgaard E, Christensen L, Berchtold MW, Panina S. 2010. Prolactin and oestrogen synergistically regulate gene expression and proliferation of breast cancer cells. Endocr. Relat. Cancer 17: 809-822.
68. Reynolds EF. 1996. Martindale: the Extra Pharmacopoeia. The Royal Pharmaceutical Society: London.
69. Rudel RA, Attfield KR, Schifano JN, Brody JG. 2007. Chemicals causing mammary gland tumors in animals signal new directions for epidemiology, chemicals testing, and risk assessment for breast cancer prevention. Cancer 109(suppl.): 2635-2666.
70. Schroeder MD, Symowicz J, Schuler LA. 2002. PRL modulates cell cycle regulators in mammary tumour epithelial cells. Mol. Endocrinol. 16: 45-57.
71. Scotti ML, Langenheim JF, Tomblyn S, Springs AE, Chen WY. 2008. Additive effects of a prolactin receptor antagonist, G129R, and herceptin on inhibition of HER2-overexpressing breast cancer cells. Breast Cancer Res. Treat. 111: 241-250.
72. Sistare FD, Morton D, Alden C, Christensen J, Keller D, DeJonghe S, Storer RD, Reddy MV, Kraynak A, Trela B, Bienvenue JG, Bjurstrom S, Bosmans V, Brewster D, Colman K, Dominik M, Evans J, Hailey JR, Kinter L, Liu M, Mahrt C, Marien D, Myer J, Perry R, Potenta D, Roth A, Sherratt P, Singer T, Slim R, Soper K, Fransson-Steen R, Stolz J, Turner O, Turnquist S, van Heerden M, Woicke J, DeGeorge JJ. 2011. An analysis of pharmaceutical experience with decades of rat carcinogenicity testing. Support for a proposal to modify current regulatory guidelines. Toxicol. Pathol. 39: 716-744.
73. Steinmetz R, Brown NG, Allen DL, Bigsby RM, Ben-Jonathan N. 1997. The environmental estrogen bisphenol A stimulates prolactin release in vitro and in vivo. Endocrinology 138: 1780-1786.
74. Stevens JT, Breckenridge CB, Wetzel L. 1999. A risk characterization for atrazine: oncogenicity profile. J. Toxicol. Environ. Health A 56: 69-109.
75. Swaminathan G, Varghese B, Fuchs SY. 2008. Regulation of prolactin receptor levels and activity in breast cancer. J. Mammary Gland Biol. Neoplasia 13: 81-91.
76. Tao J, Oladimeji P, Rider L, Diakonova M. 2011. PAK1-Nck Regulates Cyclin D1 Promoter Activity in Response to Prolactin. Mol. Endocrinol. 25: 1565-1578.
77. Tworoger SS, Hankinson SE. 2006. Prolactin and breast cancer risk. Cancer Lett. 243: 160-169.
78. Tworoger SS, Hankinson SE. 2008. Prolactin and breast cancer etiology: an epidemiologic perspective. J. Mammary Gland Biol. Neoplasia 13: 41-53.
79. Tworoger SS, Eliassen AH, Rosner B, Sluss P, Hankinson SE. 2004. Plasma prolactin concentrations and risk of postmenopausal breast cancer. Cancer Res. 64: 6814-6819.
80. Tworoger SS, Sluss P, Hankinson SE. 2006. Association between plasma prolactin concentrations and risk of breast cancer among predominately premenopausal women. Cancer Res. 66: 2476-2482.
81. Tworoger SS, Eliassen AH, Sluss P, Hankinson SE. 2007. A prospective study of plasma prolactin concentrations and risk of premenopausal and postmenopausal breast cancer. J. Clin. Oncol. 25: 1482-1488.
82. Vonderhaar BK. 1989. Estrogens are not required for prolactin induced growth of MCF-7 human breast cancer cells. Cancer Lett. 47: 105-110.
83. Vonderhaar BK. 1999. Prolactin involvement in breast cancer. Endocr. Relat. Cancer 6: 389-404.
84. Walker AM. 2006. Therapeutic potential of S179D prolactin - from prostate cancer to angioproliferative disorders: the first selective prolactin receptor modulator. Expert Opin. Invest. Drugs. 15: 1257-1267.
85. Wang DY, Hampson S, Kwa HG, Moore JW, Bulbrook RD, Fentiman IS, Hayward JL, King RJ, Millis RR, Rubens RD. 1986. Serum prolactin levels in women with breast cancer and their relationship to survival. Eur. J. Cancer Clin. Oncol. 22: 487-492.
86. Wang PS, Walker AM, Tsuang MT, Orav EJ, Glynn RJ, Levin R, Avorn J. 2002. Dopamine antagonists and the development of breast cancer. Arch. Gen. Psychiat. 59: 1147-1154.
87. Yokoro K, Nakano M, Ito A, Nagao K, Kodama Y. 1977. Role of prolactin in rat mammary carcinogenesis: detection of carcinogenicity of low dose carcinogens and of persisting dormant cancer cells. J. Natl. Cancer Inst. 58: 1777-1783.
88. Yoshimoto N, Nishiyama T, Toyama T, Takahashi S, Shiraki N, Sugiura H, Endo Y, Iwasa M, Fujii Y, Yamashita H. 2011. Genetic and environmental predictors, endogenous hormones and growth factors and risk of estrogen receptor-positive breast cancer in Japanese women. Cancer Sci. 102: 2065-2072.